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AbstrACt
Introduction Self- monitoring of blood pressure (BP) in 
pregnancy could improve the detection and management 
of pregnancy hypertension, while also empowering and 
engaging women in their own care. Two linked trials aim 
to evaluate whether BP self- monitoring in pregnancy 
improves the detection of raised BP during higher risk 
pregnancies (BUMP 1) and whether self- monitoring 
reduces systolic BP during hypertensive pregnancy (BUMP 
2).
Methods and analyses Both are multicentre, non- 
masked, parallel group, randomised controlled trials. 
Participants will be randomised to self- monitoring 
with telemonitoring or usual care. BUMP 1 will recruit 
a minimum of 2262 pregnant women at higher risk 
of pregnancy hypertension and BUMP 2 will recruit a 
minimum of 512 pregnant women with either gestational 
or chronic hypertension. The BUMP 1 primary outcome is 
the time to the first recording of raised BP by a healthcare 
professional. The BUMP 2 primary outcome is mean 
systolic BP between baseline and delivery recorded by 
healthcare professionals. Other outcomes will include 
maternal and perinatal outcomes, quality of life and 
adverse events. An economic evaluation of BP self- 
monitoring in addition to usual care compared with usual 
care alone will be assessed across both study populations 
within trial and with modelling to estimate long- term cost- 
effectiveness. A linked process evaluation will combine 
quantitative and qualitative data to examine how BP self- 
monitoring in pregnancy is implemented and accepted in 
both daily life and routine clinical practice.
Ethics and dissemination The trials have been approved 
by a Research Ethics Committee (17/WM/0241) and 
relevant research authorities. They will be published in 
peer- reviewed journals and presented at national and 
international conferences. If shown to be effective, BP 
self- monitoring would be applicable to a large population 
of pregnant women.
trial registration number NCT03334149
IntroduCtIon
Raised blood pressure (BP) affects approxi-
mately 10% of pregnancies worldwide, almost 
half of these women develop pre- eclampsia.1 
Globally, around 15% of maternal mortality is 
due to pre- eclampsia so early detection and 
prevention are paramount.2 In the UK, inade-
quate management of raised BP, in particular 
systolic hypertension, has previously been 
reported as a significant contributing factor 
to maternal deaths and although this has 
improved over the past decade, pre- eclampsia 
remains important.3 4
strengths and limitations of this study
 ► Based on current literature, these will be the largest 
randomised controlled trials of blood pressure self- 
monitoring in pregnancy completed to date.
 ► The pragmatic trial designs, with broad inclusion 
criteria, will make findings of both linked studies 
applicable to routine antenatal care.
 ► Data on the correct targets for self- monitored blood 
pressure are currently sparse.
 ► The trials are powered for primary and some sec-
ondary outcomes but the effect of self- monitoring 
on rarer secondary maternal morbidity and mortality 
outcomes will still be uncertain.
 ► Women with gestational hypertension may develop 
this late in pregnancy making it harder to show ben-
efit for interventions at this time.
O
xford. Protected by copyright.
 o
n
 February 3, 2020 at Bodleian Libraries of the University of
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034593 on 23 January 2020. Downloaded from 
2 Dougall G, et al. BMJ Open 2020;10:e034593. doi:10.1136/bmjopen-2019-034593
Open access 
Figure 1 Study design. BUMP 1, BP during higher risk pregnancy; CH, chronic hypertension; GH, gestational hypertension; 
HT, hypertension; NT, normotension.
BP self- monitoring, where an individual measures their 
own BP outside of the clinical setting, allows for multiple 
measurements providing a better estimate of the under-
lying BP than intermittent clinic measurements. Such 
self- monitoring in pregnancy could improve both the 
detection and subsequent management of gestational 
hypertensive disorders including pre- eclampsia, while 
also empowering and engaging women in their own 
care.5 6
Women who are at higher risk for raised BP in preg-
nancy (eg, due to age or previous medical history) 
may require more frequent monitoring.7 8 BP can rise 
rapidly in pregnancy and hypertension may go unde-
tected in between antenatal visits.2 Once raised BP is 
detected during the pregnancy, the clinical focus is on 
treating the hypertension, monitoring for development 
of pre- eclampsia and ensuring appropriate fetal surveil-
lance.7 Substantial resources are currently expended in 
monitoring such women, from the perspective of both 
the woman and the National Health Service (NHS).9 If 
shown to be successful, self- monitoring could provide 
more accurate data for clinicians to use for treatment 
and management strategies, safely reduce the burden of 
multiple clinic visits for women, free up time for midwives 
and therefore be a cost- effective option. Self- monitoring 
is easy to accomplish and is now commonplace in adults 
with hypertension outside of pregnancy.10 11
BP self- monitoring is, therefore, a potentially appealing 
option for both the detection and management of hyper-
tension. We have previously shown feasibility and accept-
ability of self- monitoring of BP in pregnancy.5 6 This 
trial aims to investigate self- monitoring in two groups 
by undertaking two linked, parallel group, randomised 
trials to evaluate whether self- monitoring of BP improves 
the detection of raised BP during higher risk pregnan-
cies (BUMP 1) and whether self- monitoring improves BP 
control in women with hypertensive pregnancy (BUMP 
2).
MEthods And AnAlysIs
study design and setting
The BUMP trials are two linked, multicentre, non- 
masked, parallel group, randomised controlled trials 
investigating self- monitoring of BP during pregnancy in 
the UK in secondary care maternity units (sites listed on 
https:// clinicaltrials. gov/ ct2/ show/ NCT03334149). The 
work is part of a larger programme of work investigating 
the use of self- monitoring and testing during pregnancy.
The BUMP 1 trial is a prospective non- masked 
randomised controlled trial of self- monitoring of BP 
in pregnancy for the detection of raised BP. Women at 
higher risk of pre- eclampsia will be recruited through 
antenatal clinics. The consent process for BUMP 1 will 
include discussion of the transition to BUMP 2 should a 
woman develop raised BP.
The BUMP 2 trial is a prospective non- masked 
randomised controlled trial of self- monitoring of BP for 
the management of hypertension in pregnancy in women 
with chronic hypertension (CH) or gestational hyperten-
sion (GH). Women may enter this study from BUMP 1 
(maintaining original randomisation) or be recruited 
without prior involvement. See figure 1 for an overview 
of the study design.
There will be an initial external pilot phase including 
up to 50 women in order to test trial procedures prior to 
the commencement of full recruitment.
Intervention and controls groups
Usual care
Usual care will consist of pregnant women having their 
BP measured by their usual antenatal care team, and 
initiation and/or adjustment of medication (where 
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Figure 2 BP interpretation chart for BUMP 1. BUMP1, BP during higher risk pregnancy.
appropriate) based on these measurements at the discre-
tion of the healthcare professional.
Self-monitoring
Women randomised to self- monitoring will be provided 
with a monitor validated for use in pregnancy and pre- 
eclampsia (Microlife WatchBP Home) and instructions 
for its use. Participants will be enrolled on the telemon-
itoring system, a text/app- based system and provided 
with clear instructions on its use. Participants can switch 
between the text and app system to decrease problems 
with connectivity for example, poor internet connection 
or phone signal. Access to the telemonitoring system was 
designed to have secure logins for the participants, their 
clinicians and the research team. This system was devel-
oped from our pilot work with appropriate theoretical 
underpinnings and designed by the University of Oxford, 
Department of Engineering Science, and appropriate 
functionality testing was done by the development team 
to test different combinations of normal and abnormal 
BP readings and user behaviours (eg, poor adherence 
or numerous, unrequested readings) over a prolonged 
period followed by user testing with pregnant women.6 12
BUMP 1 participants will be asked to monitor their BP 
three times a week throughout their pregnancy. They will 
be instructed to sit quietly and comfortably for 1 min, take 
two readings 1 min apart and submit their second reading 
to the telemonitoring system. Participants will receive a 
guideline with colour- coded instructions (figure 2). If 
the second reading is outside the expected range, this 
will automatically trigger a request for a third reading 
(taken after 5 min) and persistent high or low readings 
will automatically trigger a message to ask the participant 
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Figure 3 BP interpretation chart for BUMP 2. BUMP 2, BP during hypertensive pregnancy.
to contact their local maternity unit. If women have 
persistently high readings, they will be asked (via the tele-
monitoring system) to undertake daily readings for the 
rest of their pregnancy.
BUMP 2 participants will be asked to monitor their BP 
daily throughout their pregnancy. They will be instructed 
to take two measures (as above) and asked to submit their 
second reading to the telemonitoring system. Participants 
will receive a guideline with colour coded instructions 
(figure 3). High or low second readings will automatically 
trigger a request for a third reading (taken after 5 min) 
and persistent high or low readings will automatically 
trigger a message for the participant to contact their local 
maternity unit.
On the basis of the results of our pilot work and recent 
systematic review, the same thresholds will be used for self- 
monitoring as clinic BP to trigger action (ie, 140/90 mm 
Hg), therefore, resulting in alerts to participating women 
via the telemonitoring system.6 13
To improve adherence to the intervention partici-
pants will receive weekly motivational messages, and 
these messages will be sent to women in the intervention 
group via the telemonitoring system (via the app or text 
message) based on the woman’s preference. These are 
designed to provide support and education throughout 
the trial and were developed during our pilot work with 
patient and public involvement. Messages will be selected 
at random from a pool of messages (approved by the 
ethics committee). To monitor adherence and for safety 
the local clinical team will also receive warnings in real 
time via the telemonitoring system if a participant misses 
submitting readings, allowing them to approach the 
participant to troubleshoot any potential issues.
Participants will be provided with instructions in the 
use of the telemonitoring system at the baseline visit. 
Participants will manually send their readings from the 
BP monitor to a centralised database, secured behind 
NHS firewalls, using a free SMS text message or app with 
web- based data entry backup. Reminders and triggered 
messages will be received by participants according to a 
rule- based algorithm developed with the clinical team. 
Participants in BUMP 1 will receive a reminder after 
4 days without submitting a reading and then one more 
reminder the following day if no further readings are 
entered. Participants in BUMP 2 will receive a reminder 
after two missed days of readings, with a further reminder 
the following day if no further readings are entered.
Each participant has the right to discontinue the inter-
vention or withdraw from the trial at any time. In addi-
tion, an investigator may withdraw a participant from 
the trial at any time if the investigator considers it neces-
sary for any reason including: ineligibility (either arising 
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box 1 secondary outcomes for blood pressure (bP) 
during higher risk pregnancy (buMP 1) and buMP 2
Maternal outcomes
 ► Severe hypertension (systolic BP ≥160 mm Hg and/or diastolic BP 
≥110 mm Hg).
 ► Pre- eclampsia or gestational hypertension.
 ► Serious maternal complications including eclampsia, transient 
ischaemic attack or stroke, pulmonary oedema, renal failure, blood 
transfusion, HELLP syndrome, liver involvement, haematological in-
volvement and death.
 ► Onset of labour.
 ► Change in maternal quality of life from randomisation (measured us-
ing the EuroQoL 5 Dimensions 5 Levels (EQ- 5D- 5L) questionnaire).16
 ► Diastolic BP.*
 ► Area under the BP curve.*
 ► Proportion of systolic readings above 140 mm Hg.*
Perinatal outcomes
 ► Stillbirths.
 ► Early neonatal deaths.
 ► Gestation at delivery.
 ► Mode of delivery.
 ► Birth weight of the baby, including centile.
 ► Small for gestational age infants (<10th and <3rd centile).
 ► Neonatal unit admissions, including length of stay.
Process outcomes
 ► Change in health behaviours (questionnaire).
 ► Fidelity to monitoring schedule.
 ► Change in State Trait Anxiety Inventory short form 6 anxiety 
questionnaire.34
 ► Health service costs.
 ► Cost per maternal quality- adjusted life year gained over trial period.
 ► Change in adherence to medication (MARS questionnaire).*35
 ► Qualitative data gathered from participating women and healthcare 
professionals.
Outcomes common to both trials apart from. *Only assessed on BUMP 2 
participants.
during the trial or retrospectively having been overlooked 
at screening), an adverse event (AE), which results in 
inability to continue to comply with trial procedures, 
withdrawal of consent and lost to follow- up. If a woman 
discontinues the intervention, withdraws or is withdrawn 
from the study at any point, her usual antenatal care will 
continue as all study procedures are additional rather 
than in place of usual care.
Women who wish to discontinue the BP self- monitoring 
intervention will be asked if they are willing to participate 
in study follow- up. All data collected to the point of with-
drawal will be retained in the study database. Unless a 
participant specifically withdraws consent, notes review 
will be conducted if possible, even where an individual 
has been lost to follow- up.
study outcomes
Outcome definitions
 ► The onset of hypertension/high BP will be defined as 
the earliest date recorded of sustained systolic BP ≥140 
and/or diastolic BP ≥90 mm Hg from any community 
or hospital setting recorded in the notes review.
 ► Sustained is defined as at least two readings within 
1 week (168 hours), with no minimum time between 
readings needing to be recorded.
 ► The ‘earliest date recorded’ will be for the second of 
these two readings.
 ► Additionally, a new prescription of antihypertensive 
medication for raised BP will be taken as a diagnosis of 
hypertension/high BP (in order to capture diagnoses 
where medication has been started but two raised BPs 
have not been recorded in the notes review for what-
ever reason). In this case, the first date of prescription 
will be listed as the date of diagnosis.
Primary outcome for BUMP 1
The primary outcome for BUMP 1 is the difference in 
time to a recording of raised BP by a healthcare profes-
sional between the usual care and self- monitoring groups.
Secondary outcomes for BUMP 1
Secondary outcomes for BUMP 1 include analysis of the 
difference between usual care and self- monitoring groups 
as per box 1:
Primary outcome for BUMP 2
The primary outcome for BUMP 2 is the difference in 
mean systolic BPs, recorded by healthcare professionals 
from baseline to delivery, between usual care and self- 
monitoring groups.
Secondary Outcomes for BUMP 2
Secondary outcomes for BUMP 2 include analysis of the 
difference between usual care and self- monitoring groups 
as per box 1.
Participant timeline
Members of the research team will provide a full verbal 
explanation and written description of the trial to women 
who meet the inclusion criteria (box 2 and 3). The 
woman will be given sufficient time to consider the infor-
mation, and to decide whether she will participate in the 
trial. Written informed consent will be sought from the 
woman and taken by an appropriately trained healthcare 
professional. Eligibility will be assessed and baseline data, 
including all demographics, maternal demographics 
and patient questionnaires (completed by the woman), 
will be entered on a web- based database by members of 
the research team. Participants will be randomised and 
instructed in the use of self- monitoring and provided with 
a BP monitor or instructed to follow usual care. Women 
randomised to usual care will not be prevented from 
self- monitoring although we will ask all women at final 
follow- up if they have self- monitored during the trial. 
Participants on both arms will follow their routine care 
clinic visits until delivery. Participants will be contacted 
at around 30 weeks gestation (2 weeks after baseline if 
participants were recruited after 30 weeks) and asked 
either in person/over the phone/by post/or via email to 
O
xford. Protected by copyright.
 o
n
 February 3, 2020 at Bodleian Libraries of the University of
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034593 on 23 January 2020. Downloaded from 
6 Dougall G, et al. BMJ Open 2020;10:e034593. doi:10.1136/bmjopen-2019-034593
Open access 
box 2 blood pressure during higher risk pregnancy 
(buMP 1) inclusion and exclusion criteria
Inclusion criteria
 ► Participant is willing and able to give informed consent for partici-
pation in the trial.
 ► Pregnant woman, aged 18 years or above between 16+0 and 24+0 
weeks.
 ► Able and willing to comply with trial requirements.
 ► Willing to allow her general practitioner and consultant, if appropri-
ate, to be notified of participation in the trial.
 ► At higher risk for hypertension in pregnancy/pre- eclampsia defined 
as one or more of the following risk factors:
 – Age 40 years or older.
 – Nulliparity.
 – Pregnancy interval of more than 10 years.
 – Family history of pre- eclampsia.
 – Previous history of pre- eclampsia or gestational hypertension.
 – Body mass index 30 kg/m2 or above at booking.
 – Chronic kidney disease.
 – Twin pregnancy.
 – Prepregnancy diabetes (type 1 or 2)
 – Autoimmune disease (eg, systemic lupus erythematosus or anti-
phospholipid disease).
Exclusion criteria
 ► Chronic hypertension.
box 3 blood pressure (bP) during hypertensive 
pregnancy inclusion and exclusion criteria
Inclusion criteria
 ► Women with chronic hypertension (defined as sustained systolic BP 
≥140 mm Hg and/or diastolic BP ≥90 mm Hg, present at booking or 
before 20 weeks gestation, or receiving antihypertensive treatment 
outside pregnancy and/or at time of referral), recruited up to 37+0 
weeks gestation.
or
 ► Women with gestational hypertension after 20 weeks gestation 
(defined as sustained systolic BP ≥140 mm Hg and/or diastolic BP 
≥90 mm Hg), recruited at 20+0 to 37+0 weeks gestation.
And
 ► Participant is willing and able to give informed consent for partici-
pation in the trial.
 ► Woman aged 18 years or above.
 ► Willing to allow her general practitioner and consultant, if appropri-
ate, to be notified of participation.
Exclusion criteria
 ► Anticipated inpatient admission considered likely to lead to immi-
nent delivery (within the next 48 hours).
complete patient questionnaires. The remainder of ante-
natal care, in particular the timing and mode of delivery, 
will be left to the discretion of the responsible clinician. 
A medical notes review will be undertaken following the 
primary discharge for mother and baby. If a woman and/
or her baby is still in hospital at 2 months from delivery or 
2 months from her estimated date of delivery (whichever 
is longer), the admission time will be censored and data 
collected up to that point. Self- monitoring of BP will 
finish at admission in established labour or the end of 
pregnancy, whichever is sooner and participants will 
continue with standard postnatal care. Participants will 
be contacted at around 8 weeks postdelivery and asked 
either in person/over the phone/by post/or via email to 
complete patient questionnaires and arrange for collec-
tion of the loaned BP monitor if not returned at delivery. 
A schedule of participant enrolment, interventions and 
assessments in the trial is shown in table 1 and a flowchart 
of study visits is shown in figures 4 and 5.
sample size considerations
BP during higher risk pregnancies
The sample size was determined using a two- stage simula-
tion process, which modelled how many women would be 
expected to develop hypertension and how long time to 
detection would take in these women, using data from our 
pilot work in the BUMP study. Assuming 16% of women 
develop hypertension, and an SD of 40 days to detection 
of raised BP in both groups, a sample size of 2262 (1131 
per group) will allow detection of an effect size of 12 day’s 
difference in time to detection of raised BP in pregnancy 
between self- monitoring and control groups (the primary 
outcome of BUMP 1), with 90% power and 5% level of 
significance (two sided) and assuming a 15% attrition 
rate. If the SD is 45 days, then this sample size will allow 
detection of a difference of 14 days with more than 90% 
power and if the SD is 50 days then it will be sufficient 
to detect a difference of 16 days in time to detection 
of raised BP in pregnancy also with 90% power. Of the 
2262 women recruited to BUMP 1, around 362 women 
are expected to develop hypertension. We will recruit a 
minimum of 2262 women to ensure adequate power. The 
simulation was carried out using R V.3.1.2. (https://www. 
r- project. org/).
BP during hypertensive pregnancy
A sample size of 256 per group will be sufficient to detect 
a 5 mm Hg difference in systolic BP between groups, 
accounting for 15% attrition and an SD of 16 mm Hg, 
based on data from the BUMP pilot and PELICAN 
studies, inflated from 14 mm Hg because BUMP 2 will 
include hypertensive women from BUMP 1 and those 
with chronic or GH not previously randomised in BUMP 
1.6 14 The sample size was calculated using NCSS PASS 
V.12.0.
Women randomised in BUMP 1 who develop hyper-
tension will remain in their randomisation groups and 
move seamlessly into the BUMP 2 trial. This will occur 
automatically via the telemonitoring system and their 
inclusion in BUMP 2 assessed retrospectively. The precise 
numbers and proportion of women migrating from 
BUMP 1 to BUMP 2 will not be fixed. We will aim to 
recruit a minimum of 512 women directly into the BUMP 
2 trial in addition to those that migrate in order to ensure 
adequate power: women who have CH or have developed 
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Table 1 Schedule of interventions and assessments
Study period
(16 weeks to 8 weeks postdelivery)
Study visit Trial entry/baseline Antenatal follow- up Notes review Postnatal follow- up
Time point
20±4
weeks gestation
30±3
weeks
gestation
40+4
weeks 
(postdelivery)
40+8
weeks (postdelivery)
Informed consent X       
Eligibility assessment X       
Demographics; including age, race, 
education
X       
Maternal demographics; including 
gestation, EDD and parity
X       
Patient Questionnaires; including EQ- 
5D- 5L and STAI
X X   X
Randomisation X       
Recording home BP Self- Monitoring group will record and submit reading between 
baseline and delivery
  
Recording clinic BPs     X   
Maternal and perinatal outcomes     X   
Secondary outcome data     X   
Return of BP monitor     BP monitors will be returned at/or 
postdelivery
BP, blood pressure; EDD, Estimated Delivery Date; EQ- 5D- 5L, EuroQoL 5 Dimensions 5 Levels; STAI, State- Trait Anxiety Inventory.
GH and are not taking part in the BUMP 1 trial will be 
randomised to either usual care using clinic BP to guide 
treatment or BP self- monitoring with telemonitoring and 
automated feedback.
Both trials will be undertaken in approximately 15 
maternity units in England to achieve the sample size in 
the anticipated time frame. Our previous pilot trial has 
confirmed that women and clinicians are willing to partic-
ipate in this type of randomised controlled trial and we 
have used recruitment estimates from this trial, together 
with trial management experience and expertise of the 
coinvestigator group to inform strategies to meet the 
required target size.6
data management
An online clinical data management system will be used, 
with all clinical data entered directly onto the elec-
tronic case report forms (CRFs) and stored on a study- 
specific database. Paper backup forms will be available if 
the online database cannot be accessed. Data collected 
on paper forms will be entered on to the database at 
the earliest opportunity, by single data entry. Patient- 
completed questionnaires will be completed directly on 
to the system by the participant wherever possible, with 
manual single data entry of paper copies if required. 
Telemonitored mHealth data are stored on a centralised 
database, secured behind NHS firewalls, designed and 
maintained by the University of Oxford, Department of 
Engineering Science.
randomisation
Women who agree to participate in the trial (BUMP 1 or 
BUMP 2) will be randomised on a 1:1 ratio either to BP 
self- monitoring or usual care by the recruiting researcher. 
An independent statistician will generate a randomisa-
tion sequence list for each trial, using permutated varying 
blocks and stratified by recruitment site and parity. The 
generated schedules were then imported to the randomi-
sation module within the online data management system 
for site to carry out the randomisation. Women will be 
randomised by the recruiting researcher using the online 
data management system. Women who develop hyperten-
sion during BUMP 1 and migrate to BUMP 2 will stay in 
their original randomisation group. A manual telephone 
based backup randomisation system will be used in the 
event the online system is not available.
statistical analysis
General consideration for both trials
The primary statistical analysis will be carried out on 
the basis of intention to treat (ITT). Thus, after rando-
misation participants will be analysed according to their 
allocated treatment group irrespective of what treat-
ment they actually receive. We will endeavour to obtain 
full follow- up data on every participant to allow full ITT 
analysis, but we will inevitably experience the problem 
of missing data due to withdrawal, lost to follow- up, or 
non- response questionnaire items. The results from the 
trial will be prepared as comparative summary statistics 
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Figure 4 BUMP 1 study visit chart. BP, blood pressure; 
BUMP 1, BP during higher risk pregnancy.
Figure 5 BUMP 2 study visit chart. BP, blood pressure; 
BUMP 2, BP during hypertensive pregnancy.
(eg, difference in means) with 95% CIs. The study results 
will be reported in accordance with the Consolidated 
Standards of Reporting Trials 2010 statements and full 
detailed statistical analysis plans will be prepared before 
the final analysis by an independent statistician.
BP during higher risk pregnancy
The primary analysis will determine whether there 
is a difference in the time to diagnosis between the 
randomised groups (usual care vs self- monitoring) and 
will be performed using a two- part model, such as the 
hurdle model.15 The model takes into account partici-
pants who developed a raised BP or not and the time to 
raise BP, adjusting for stratification factors. This method 
has the advantage that all women who are recruited to 
BUMP 1 will contribute to the primary analysis. Contin-
uous secondary outcomes, such as birth weight and length 
of stay, will be analysed by means of regression method 
adjusting for stratification factors. Binary secondary 
outcomes, such as the development of severe hyperten-
sion, development of any complications and stillbirth 
rate, will be analysed by means of a log binomial model.
BP during hypertensive pregnancy
An ITT analysis will include women recruited to BUMP 1 
who become hypertensive and women recruited de novo 
to BUMP 2 with GH and CH analysed separately. The 
primary analysis for BUMP 2 will in each case compare BPs 
between the intervention and control groups. Analysis of 
the BP outcome will be by means of a linear mixed- effects 
model, which can accommodate data where participants 
have repeated measurements, and also accounts for 
missing data (assuming data are missing at random). Each 
of a participant’s BP measures will be modelled by means 
of a linear mixed- effects model, including random effects 
for participants and assuming an unstructured variance 
covariance matrix between measurements from the same 
participant. Time of BP measurement and randomised 
group, as well as their interaction term, will be included 
as fixed effects in the model. A fixed effect will also be 
included for whether the participant was from BUMP 1 or 
not in the GH analysis. As a sensitivity analysis inclusion 
from BUMP 1 or not will be tested as a moderator of the 
treatment effect. By means of appropriate contrasts, the 
difference in mean BP of participants in the randomised 
groups from both BUMP 1 and de novo recruitment will 
be compared.
BP load and area under the curve will be analysed as 
continuous outcomes by means of a linear regression 
model, adjusting for whether the participant originated 
from BUMP 1. Continuous secondary outcomes, such as 
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birth weight and length of stay, will be analysed by means 
of regression model. Binary secondary outcomes, such 
as the development of severe hypertension, incidence of 
complications and incidence of stillbirth, will be analysed 
by means of a log binominal model.
Subgroup analyses
For both BUMP 1 and BUMP 2 prespecified subgroups 
include eligibility for aspirin prescription to prevent pre- 
eclampsia (as per National Institute for Health and Care 
Excellence); gestational age at baseline (≤20 weeks vs >20 
weeks), parity (0 vs ≥1). In addition, a sensitivity analysis 
will compare those women with GH that are recruited de 
novo into BUMP 2 with those that migrate from BUMP 1.
Economic evaluation
The economic evaluation component aims to determine 
whether BP self- monitoring in addition to usual care 
represents value for money compared with usual care 
alone in a population of higher risk pregnant women 
(BUMP 1) and women with a diagnosis of hypertension 
during pregnancy (BUMP 2). Two separate within- trial 
cost- effectiveness analyses will be carried out alongside 
BUMP 1 and BUMP 2. In addition, a decision analyt-
ical model will be built to determine the long- term cost- 
effectiveness of self- monitoring in pregnancy. A UK NHS 
perspective will be adopted in all analyses.
The within- trial cost–utility analyses will use individual 
patient- level data with a time horizon up to 2 months 
following delivery. The main health outcome measure in 
the economic evaluation will be maternal quality- adjusted 
life years (QALYs) over the trial period. The calculation 
of a QALY profile for each woman will be informed using 
data from the health- related quality of life instrument 
EQ- 5D- 5L that will be collected at baseline, 30 weeks gesta-
tion and 8 weeks after birth.16 A linear change between 
utility measures at each time period will be assumed when 
deriving an individual’s QALY profile. Relevant health-
care resource use during the pregnancy for mothers and 
their fetuses will include antenatal, intrapartum and post-
natal care. Antenatal care utilisation will include primary 
and secondary care visits including hospital admissions. 
Intrapartum and related postnatal care before primary 
hospital discharge will include major procedures under-
taken, length of stay and transfers for mothers and their 
babies. Primary and secondary care resource utilisation 
during the trial will be collected using case note review 
including routine and additional clinic visits to midwives 
and general practitioners (GPs). Unit costs will be 
extracted from primarily national sources.17–19 The cost 
of using an automated monitor along with the telemon-
itoring system will be estimated and included in the cost 
analysis of the self- monitoring group in each trial. Mean 
maternal QALYs and costs (and associated uncertainty) 
will be estimated parametrically in the intervention and 
usual care group in each of the trials. If necessary, we will 
use multiple imputation methods to deal with missing 
EQ- 5D- 5L and resource use data over the trial period and 
will follow current guidance to conduct and report such 
analysis.20
The long- term decision analytical model will include a 
decision tree to represent women’s pathways up to the 
first 8 weeks postdelivery and a Markov model repre-
senting the history of disease of women with raised BP 
after that point, using annual cycles. The structure of the 
model will be based on models identified via a systematic 
review of previous economic evaluations of hypertensive 
patients in pregnancy (currently in progress with PROS-
PERO number: 123881). Observed risk factors, quality of 
life and healthcare resource utilisation for randomised 
participants in BUMP 1 and BUMP 2 will be used to 
inform the characteristics of a hypothetical cohort 
entering the model for each treatment pathway. Tran-
sition probabilities indicating movement across health 
states will be informed by cardiovascular risk predictions 
modified using the literature on risk following hyperten-
sive pregnancy. Costs incurred annually in each health 
state will be obtained from the literature differentiating 
between acute and chronic disease health states. Health- 
related quality of life associated with each health state in 
the model will also be obtained from the literature.
Both the within- trial cost- effectiveness analysis and 
long- term model will be reported using current reporting 
standards for economic evaluations.21 Mean differences 
in costs and QALYs between intervention and usual care 
arms in each trial and the model will be combined to 
generate an incremental cost- effectiveness ratio (ICER), 
presented as cost per QALY gained. Uncertainty around 
ICERs will be handled using CIs (if appropriate) and cost- 
effectiveness acceptability curves. Uncertainty in the long- 
term model will be assessed using probabilistic sensitivity 
analysis. Recent guidance will also be used to report and 
interpret the results from the decision analytical model.22
Process evaluation (qualitative and quantitative)
Alongside the trial, we will undertake a process evalua-
tion to assess both quantitative (including the outcomes 
listed in box 1 above) and qualitative aspects. Interven-
tion fidelity will be assessed for women and participating 
professionals. This will include for the women: exam-
ining persistence with self- monitoring and comparing 
submitted readings and monitor downloads for a subset 
of women. For the professionals, a staff survey will assess 
practice in terms of utilisation of self- monitored BP read-
ings during the trial.
In addition to the quantitative process evaluation, 
a qualitative study will be conducted within the trial to 
understand how BP self- monitoring in pregnancy is 
implemented and its acceptability in daily life and routine 
clinical practice. In- depth interviews will be completed 
with a sample of participating women in both BUMP 1 
and BUMP 2 and healthcare professionals.23
Participating women: The study aims to include approx-
imately 40 pregnant women across five sites, including a 
sample of up to eight women who decide not to take part 
or discontinue from the intervention and are willing to 
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be interviewed.24 The interviews with women will look to 
understand real- life implementation issues with BP self- 
monitoring. Women who have consented to contact at 
main trial enrolment will be contacted by phone/email/
in person regarding the interviews and provided with a 
patient information sheet (PIS); they will be consented 
separately prior to the start of the interview. Addition-
ally, an ethnographic study will follow a sample of 10–15 
women who monitor their BP.25 This ethnographic 
study will include longitudinal interviewing and non- 
participatory observations to understand in detail how 
women engage with home monitoring over time and 
whether and how home BP readings are incorporated 
into clinical encounters.26 27
Healthcare professionals: Interviews will be conducted 
with 30–40 midwives and obstetricians who are involved 
in BUMP 1 and BUMP 2.24 The aim is to understand how 
self- monitoring is operationalised in practice and provide 
key information for the process evaluation.
Detailed field notes will be taken of observations. Inter-
views will be audio recorded so that content can be tran-
scribed. Data collection and analysis will be guided by 
theory, including social cognitive theory, a ‘technology 
in practice’ perspective and normalisation process theory 
as interpretative frameworks to understand how the trial 
intervention ‘fits’ within existing practices and systems, 
and how it becomes embedded (or not) in women’s lives 
and healthcare professionals’ routine work.28–31 Inductive 
and deductive approaches to categorising and coding the 
data will be combined, drawing on a priori theoretical 
concepts (including, g, self- efficacy, unexpected use of 
technology and cognitive participation) while remaining 
sensitive to themes that emerge from the data them-
selves. An iterative analytical process will be employed to 
map the range of phenomena and identify associations 
between themes with the aim of illuminating the mecha-
nisms that underpin the outcomes of the intervention.32 
QSR NVivo will be used to support the organisation and 
retrieval of the qualitative data.33
data monitoring
Regular monitoring will be performed by the trial team 
according to Good Clinical Practice (GCP) and Clinical 
Trial Unit standard operating procedures. Data will be eval-
uated for compliance with the protocol and accuracy in 
relation to source documents. Following written standard 
operating procedures, the monitors will verify that the 
clinical trial is conducted and data are generated, docu-
mented and reported in compliance with the protocol, 
GCP and the applicable regulatory requirements.
A trial steering committee (TSC) and data monitoring 
committee (DMC) will be convened and review trial 
progress every 6 months. The TSC will provide overall 
supervision of the trial and ensure its conduct is in accor-
dance with the principles of GCP and the relevant regu-
lations. The TSC will agree the trial protocol and provide 
advice to the investigators on all aspects of the trial. The 
TSC will include members who are independent of the 
investigators, in particular an independent chairperson. 
The independent DMC will inform the TSC regarding the 
accruing trial and safety data, to ensure trial site staff and 
participants are aware of any relevant safety information 
and to advise the TSC regarding the appropriateness of 
continuation of the trial. Any consideration of the need 
for termination of the trial will be on the advice of the 
DMC and TSC who will consider the need for prospective 
criteria for termination.
harms/potential risks
During these randomised controlled trials, participants 
will continue to receive ‘usual care’ regardless of rando-
misation group, and thus we anticipate that the potential 
risks are low. Particular issues include the possibility of 
increased anxiety due to the study. Training of partic-
ipants will cover repeated measurements in the case of 
unusually high or low readings. The participant guide-
line/booklet will give clear advice to women to contact 
the antenatal care team or other healthcare professional 
(eg, GP) in the case of persistent high or low readings. 
The telemonitoring system will automatically provide this 
advice when high or low readings are sent in. Women will 
continue to be seen by their clinical teams (midwives/
GPs/obstetricians) at frequencies chosen by their clini-
cians throughout, regardless of randomisation group.
Participants will be advised to seek immediate medical 
help if they experience any symptoms of pre- eclampsia, 
regardless of their BP readings.
It is not anticipated that the study intervention (self- 
monitoring of BP) should result in any AEs but collection 
of such events will be included in case such events occur 
so that they can be considered for causal links to the study. 
Only AEs that are clinically judged (by the supervising 
site principal investigator) as being caused by the trial 
intervention will be reported to the Clinical Trials Unit 
to raise appropriately to the sponsor/Research Ethics 
Committee that gave favourable opinion. In addition, 
any maternal death or stroke, fetal loss or neonatal death 
will be reported to the DMC regardless as to whether they 
are judged related. Side effects as stated in the British 
National Formulary will not be reported as AEs.
EthICs And dIssEMInAtIon
Ethics approval and consent to participate
Any subsequent protocol amendments will be agreed with 
both sponsor and ethics committee prior to implementa-
tion. The study sponsor reviewed and ensured all indem-
nity and insurance requirements for the trial were in place 
prior to the start of recruitment which would operate in 
the event of any participant suffering harm as a result of 
their involvement in the research. NHS indemnity oper-
ates in respect of the clinical treatment that is provided. 
Participants will provide written informed consent prior 
to enrolment. An independent trial steering group will 
monitor study progress assisted by an independent DMC 
and will periodically review the study.
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Confidentiality
The trial staff will ensure that the participants’ anonymity 
is maintained in the trial database. The participants 
will be identified only by a participant identification 
number on all trial documents and any electronic data-
base. Women’s identifiers (names, address and phone 
number) will be held securely and separately from the 
CRFs where they are needed to contact participants on an 
ongoing basis, for example, for follow- up and return of 
BP monitor. Access to these data will be strictly on a need 
to know basis. All documents will be stored securely and 
only accessible by trial staff and authorised personnel. 
The study will comply with the Data Protection Act and 
General Data Protection Regulation 2018, which requires 
data to be anonymised as soon as it is practical to do so.
Patient and public involvement
Methods of patient approach, PIS and consent form 
were all reviewed by the patient representatives prior to 
formal approval. The relevant group for women with pre- 
eclampsia, ‘Action on Pre- Eclampsia’ are formally repre-
sented through their chief executive officer (MG) who is a 
coinvestigator. The TSC includes an independent patient 
representative who is jointly responsible for overseeing 
the conduct of the trial with the rest of the committee.
dissemination
All research outputs from this work will be published in 
peer- reviewed journals, presented at scientific confer-
ences and lay and social media (eg, Twitter, blogs). All 
trial data are the property of the chief investigator and 
will be stored until the end of the study, database lock 
and final analysis. All research data and documentation 
will be appropriately archived for at least 5 years. ‘Patient 
friendly’ study summary documents and infographics will 
be made available to all participants at the end of the trial 
via the study website.
dIsCussIon
This article describes the protocol for the BUMP trials. 
These randomised controlled trials will assess whether 
self- monitoring of BP during pregnancy, over and above 
usual care, can improve the detection of raised BP during 
pregnancy and whether self- monitoring can improve the 
control of BP in pregnancy hypertension.
Additional work will show whether self- monitoring BP 
is acceptable to pregnant women and their healthcare 
professionals and if it is cost- effective compared with 
usual care.
The results of the trial will provide data on the effects 
of self- monitoring and telemonitoring, over and above 
usual care, in pregnant women at risk for pre- eclampsia 
and women with hypertension.
If self- monitoring of BP is found to be successful in the 
detection of hypertension in pregnancy and control of BP 
in pregnancy hypertension, then it would be applicable 
to a large group of pregnant women in the UK but also 
worldwide.
Current trial status
The trials commenced recruitment on 11 September 
2017 (external pilot) with main recruitment starting 
on (22 November 2017) and recruitment is planned to 
continue until end of September 2019. Data collection 
will continue to mid-2020.
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